Frenova, Nephronomics and GENEWIZ collaborate on kidney disease research

BAD HOMBURG, Germany - Fresenius Medical Care announced Thursday that its research organization Frenova has partnered with Nephronomics and GENEWIZ by Azenta Life Sciences to advance genomic analysis for kidney disease research.

The collaboration will focus on Frenova’s My Reason genomics research program, a registry of genomic and clinical patient data designed to uncover insights into genetic mechanisms of kidney disease. The program has registered more than 35,000 participants who have provided biospecimens, with a goal of reaching 50,000 participants within two years.

GENEWIZ will apply DNA sequencing technologies to generate genomic data from biospecimens collected through Frenova’s nephrology research network. Azenta, with a market capitalization of $1.53 billion and revenue growth of 8.56% over the last twelve months, will also provide long-term storage of samples through its global biorepository network. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.22 and holds more cash than debt on its balance sheet.

"Kidney disease affects each individual differently, shaped by their unique biology and genetic makeup," said Frank Maddux, Global Chief Medical Officer at Fresenius Medical Care AG. "These differences influence not only how the disease manifests, but also which treatments and therapies are most effective."

Nephronomics, a joint venture between Mechanica Partners and Fresenius Medical Care, holds exclusive commercial rights to the My Reason dataset. The company aims to develop targeted therapies for cardio-kidney-metabolic diseases through precision medicine insights.

The collaboration represents an effort to better understand kidney, cardiovascular, and metabolic diseases while advancing precision medicine approaches. By analyzing genetic information, researchers hope to enable more targeted treatments, diagnostics, and preventative strategies for patients with kidney-related conditions. InvestingPro analysis reveals that Azenta’s financial health score is rated as GOOD, suggesting strong operational stability for this strategic initiative. Discover more insights about Azenta and over 1,400 other stocks with InvestingPro’s comprehensive research reports.

Fresenius Medical Care operates 3,675 dialysis clinics worldwide, providing treatments for approximately 299,000 patients. The company is listed on both the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS). While Azenta trades at a relatively high EBITDA multiple of 37.8x, InvestingPro analysis indicates the stock is currently undervalued based on their proprietary Fair Value model.

The information in this article is based on a press release statement from Fresenius Medical Care.

In other recent news, Azenta Inc. reported its second-quarter fiscal year 2025 earnings, with revenue reaching $143 million, slightly exceeding forecasts. However, the company’s earnings per share (EPS) came in at $0.05, missing the anticipated $0.08. Despite this earnings miss, the company’s revenue growth has been noted as strong, reflecting positive strategic initiatives. Additionally, Azenta announced the resignation of Violetta Hughes, its Vice President and Chief Accounting Officer, effective August 6, 2025. The company clarified that her departure is voluntary and not due to any disagreements with the company’s operations or financial matters. These developments come amid ongoing interest in Azenta’s strategic direction and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.